Physician profile
Jeffrey Loria
NPI 1912962069
$14,183.67
in general payments reported to CMS, 2019-2025
48 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $1,315 · 2021: $2,034 · 2022: $1,989 · 2023: $2,607 · 2024: $2,663 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,268.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,611.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,845.74 | 2019-2025 | Entyvio, Takhzyro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,523.86 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Glaxosmithkline, LLC. | $1,499.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Qol Medical, LLC | $999.31 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $748.24 | 2021-2024 | Zeposia |
| Kaleo, INC. | $691.54 | 2019-2024 | Auvi-Q |
| Ferring Pharmaceuticals INC. | $606.26 | 2019-2023 | Clenpiq |
| Merck Sharp & Dohme LLC | $370.20 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $273.39 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $252.03 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $238.49 | 2019-2020 | |
| Amgen INC. | $207.95 | 2019-2024 | Tezspire |
| Biocryst US Sales Co., LLC | $178.64 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $176.53 | 2020-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Loria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.